Show simple item record

dc.contributor.authorLadhani, Shamez N
dc.contributor.authorCordery, Rebecca
dc.contributor.authorMandal, Sema
dc.contributor.authorChristensen, Hannah
dc.contributor.authorCampbell, Helen
dc.contributor.authorBorrow, Ray
dc.contributor.authorRamsay, Mary E
dc.date.accessioned2018-05-08T02:38:06Z
dc.date.available2018-05-08T02:38:06Z
dc.date.issued2014
dc.identifier.issn0163-4453
dc.identifier.doi10.1016/j.jinf.2014.07.002
dc.identifier.urihttp://hdl.handle.net/10072/172005
dc.description.abstractObjectives: To assess the potential use of a protein-based meningococcal group B (MenB) vaccine (Bexsero®) in addition to antibiotic chemoprophylaxis for preventing secondary cases. Methods: Published studies on the risk of secondary meningococcal infections were used to estimate the numbers needed to vaccinate (NNV) with Bexsero® to prevent a secondary case in household and educational settings. Results: Most secondary cases occur within a few days of diagnosis in the index case. Unlike conjugate vaccines, early protection offered after a single dose of Bexsero® is likely to be low, particularly in young children, who are at higher risk of secondary infection. NNV was dependent on predicted meningococcal strain coverage, estimated onset of protection after one Bexsero® dose and estimated vaccine efficacy. Even in the most favourable scenario where we assume the vaccine is administered within 4 days of the index case and prevents 90% of cases occurring after 14 days, the NNV for household contacts was >1000. NNV in educational settings was much higher. Conclusions: The estimated NNV should be taken into account when deciding policy to recommend Bexsero® for close contacts of single cases in household or educational settings. Bexsero® may have a protective role in clusters and outbreaks
dc.description.peerreviewedYes
dc.languageEnglish
dc.language.isoeng
dc.publisherW.B. Saunders
dc.relation.ispartofpagefrom470
dc.relation.ispartofpageto480
dc.relation.ispartofissue5
dc.relation.ispartofjournalJournal of Infection
dc.relation.ispartofvolume69
dc.subject.fieldofresearchClinical sciences
dc.subject.fieldofresearchcode3202
dc.titlePreventing secondary cases of invasive meningococcal capsular group B (MenB) disease using a recently-licensed, multi-component, protein-based vaccine (Bexsero®)
dc.typeJournal article
dc.type.descriptionC1 - Articles
dc.type.codeC - Journal Articles
gro.hasfulltextNo Full Text
gro.griffith.authorSlack, Mary P.


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record